In The News Posted August 16, 2019 Share Posted August 16, 2019 STOCKHOLM, Aug. 16, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the acceptance of an oral late breaking presentation providing updated melflufen data from the Phase 2 pivotal OP-106 HORIZON study as well as two poster presentations at the 17th... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.